Get the Stockscreener App
17.92
16.51%
2.54
Pre-market:
17.60
-0.32
-1.79%
Uniqure N V stock is traded at $17.92, with a volume of 2.09M.
It is up +16.51% in the last 24 hours and up +15.39% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$15.38
Open:
$15.48
24h Volume:
2.09M
Relative Volume:
0.67
Market Cap:
$1.12B
Revenue:
$16.10M
Net Income/Loss:
$-198.97M
P/E Ratio:
-5.1481
EPS:
-3.4809
Net Cash Flow:
$-183.99M
1W Performance:
+3.05%
1M Performance:
+15.39%
6M Performance:
-71.11%
1Y Performance:
+100.67%
1-Day Range:
$15.40
$18.20
1-Week Range:
$13.21
$18.20
52-Week Range:
$8.66
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
17.92 | 961.70M | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
440.05 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.46 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
809.27 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.00 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.64 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure N.V. Lawsuit – QURE - GlobeNewswire
QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - Bakersfield.com
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
uniQure N.V. 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.QURE - ACCESS Newswire
QURE DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds uniQure N.V. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - PR Newswire
uniQure's Approval Process Hits a Roadblock—Savvy Investors Are Pulling Out Ahead of Further Declines - Bitget
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
uniQure Investors Face Deadline in Class Action Lawsuit - National Today
Barclays reaffirms equal weight rating for uniQure (QURE) - MSN
uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V.QURE - Business Wire
QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Bluefield Daily Telegraph
QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders ... - Bluefield Daily Telegraph
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. - GlobeNewswire
Energy Moves: Will uniQure NV benefit from geopolitical trendsWeekly Trading Summary & Safe Entry Point Alerts - baoquankhu1.vn
uniQure N.V. (NASDAQ: QURE) Investor Alert: Deadline in Lawsuit on April 13, 2026 - openPR.com
QURE FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors with Losses ... - Caledonian Record
QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - ChartMill
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
INVESTOR DEADLINE: uniQure (QURE) Investors with - GlobeNewswire
William Blair Downgrades uniQure N.V. (QURE) - MSN
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears - The Malaysian Reserve
QURE Stockholders Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - GlobeNewswire Inc.
FDA Criticizes uniQure's Gene Therapy, Lawsuit Filed - National Today
QURE Shareholder Alert: uniQure N.V. Securities Class Action Law - GuruFocus
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - TMX Newsfile
QURE Shareholders Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
Press releases provided by CNW - Techaeris
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
Investors in uniQure N.V. Should Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights – QURE - GlobeNewswire
uniQure N.V. Faces Class Action Lawsuit Deadline - National Today
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
UNIQURE N.V. (NASDAQ: QURE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises ... - Caledonian Record
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
QURE INVESTOR NOTICE: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears - The Malaysian Reserve
ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors ... - Caledonian Record
UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, - GlobeNewswire
uniQure Faces FDA Rebuke as Shareholder Class Action Filed - Intellectia AI
uniQure Approaches April 13 Court Deadline Amid Stricter FDA Position on Gene Therapy Study - Bitget
(QURE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
QURE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QU - GuruFocus
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.62%
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):